Press Releases Year None2021202020192018201720162015201420132012 Aug 30 Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months Aug 24 Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration Aug 20 UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection Aug 5 Regeneron Reports Second Quarter 2021 Financial and Operating Results Aug 5 Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer Aug 4 New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection Aug 3 Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation Jul 30 FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab) Jul 29 Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients Jul 27 Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page »